Aims-To determine if allelic loss on chromosomes 16q and 17p, commonly encountered in in situ and invasive ductal carcinomas, is present in atypical ductal hyperplasia (ADH); to determine whether ADH is a neoplastic (clonal) or hyperplastic (polyclonal) proliferation. Methods-Fourteen cases of ADH were exaniined for allele loss at loci on chromosome 16q and 17p using a microdissection technique, polymorphic DNA markers and the polymerase chain reaction (PCR). Results-Loss of heterozygosity (LOH) was detected in five of nine informative cases on chromosome 16q at the microsatellite D16S413 and two of eight informative cases on chromosome 17p at D17S796. Conclusions-The incidence of LOH at these loci is similar to that previously observed in ductal carcinoma in situ and in invasive ductal carcinoma. Because of the nature of the technique used, our findings also demonstrate that ADH is a monoclonal, and hence, neoplastic proliferation rather than a hyperplastic (polyclonal) condition as its name suggests. There is thus a case for including ADH, as presently defined, within the spectrum ofductal carcinoma in situ. (J7 Clin Pathol 1995;48:611-615) Keywords: Breast cancer, atypical ductal hyperplasia, loss of heterozygosity.
With increasing use of mammographic screening, ductal carcinoma in situ is being encountered with greatly increased frequency by histopathologists.' A major problem with ductal carcinoma in situ is distinguishing certain variants from intraductal hyperplasia. The high nuclear grade forms particularly with comedo type necrosis, can be diagnosed with a high level of consistency but the low nuclear grade types may be very difficult to distinguish from the group of proliferations collectively known as atypical ductal hyperplasia (ADH), which exhibit some, but not all, features of ductal carcinoma in situ.45 To address this problem, Page and Rogers6 laid down clear criteria for diagnosing ADH based on combined histological and cytological features. Despite the use of these strict criteria, a recent study in which cases ofhyperplasia ofusual type (HUT), ADH and ductal carcinoma in situ were examined by six experienced breast pathologists showed complete agreement in only 58% of cases. 7 Given the similarity of ADH to ductal carcinoma in situ of low nuclear grade, it would clearly be of value to learn more about these processes at the molecular level, particularly if such investigations led ultimately to the development ofmore objective diagnostic criteria.
We have recently developed methodology for detecting allele loss in microscopic lesions dissected from formalin fixed, paraffin wax embedded tissue using the polymerase chain reaction (PCR Of the 10 informative cases, five showed LOH. All five showed at least one focus with LOH at 16q and two of these cases also had loss of 17p (figs 1 and 2). Two of five cases exhibiting LOH were associated with in situ and invasive carcinoma while the other three cases had benign changes only, including cysts, HUT and radial scars. As can be seen from the table, the sizes of the lesions in cases exhibiting LOH range from 1-0 to 4-5 mm and the disease extent from focal to extensive. The age range was 46-86 years (mean 61 8 years).
More than one separate focus of ADH was examined from the same breast in three of five informative cases. Identical results were obtained with each focus from any particular case with the exception of 259 where LOH on 16q was found in one focus of ADH but not in the other.
The five cases which did not show LOH in any sample at either locus had a similar age distribution ranging from 49 to 65 years (mean 57-7 years). Three cases had associated in situ and invasive carcinoma, one had benign changes and the fifth was otherwise normal. All lesions were small ranging from 04 to 2-0 mm and four of five were focal.
We did not detect any significant morphological differences between the cases with and without LOH. In all the cases the estimated level of contamination by stromal or inflammatory cells did not exceed 5%.
Some of the cases of ADH had adjacent in situ and invasive carcinoma. Data on LOH in these lesions are not presented here as they are not deemed to be relevant to the present study, especially as allelic loss in ADH has also been identified in otherwise benign breast biopsy specimens.
Discussion
Using a microdissection technique to isolate small foci of ADH and by amplifying polymorphic dinucleotide repeats (microsatellites) using PCR, we have shown that halfofour cases of ADH, as defined by Page and Rogers,6 were monoclonal proliferations exhibiting allelic loss at loci on chromosomes 16q and 17p. It is likely that the other halfwere also monoclonal given that they were morphologically identical; however, they lacked detectable deletions at the precise loci studied. The incidence of LOH is similar to that already found in ductal carcinoma in situ of high and low nuclear grade8 and which has been found in invasive ductal carcinoma by other authors using Southern analysis.'0 That the detection of LOH in ADH was due to extension of nearby carcinoma cells is excluded by the lack of malignancy in three cases and the cytological dissimilarity of the in situ and invasive malignancy in the other two cases (table). Where more than one focus was examined from the same case, the pattern of LOH was the same with one exception where two foci differed with respect to the 1 6q deletion. Whether this reflects aspects of methodology or genuine subclonal heterogeneity is not yet clear. The former is possible, particularly as the gels were reported very conservatively and LOH was recorded only when a very obvious result was obtained.
It is possible to determine allelic loss using the method we have described only when the sequence amplified by PCR is lost from the great majority of cells in the proliferation.
Where significant numbers of cells have retained the relevant allele, the PCR will amplify it sufficiently to produce a second band and hence obscure the deletion that would otherwise be identified. The most likely explanation for the presence of allelic loss in a cell population is that they are all descendants of a single cell in which the genetic lesion first occurred. The alternative explanation that all the cells acquired an identical genetic lesion independently is highly improbable. Consequently, our findings indicate that ADH is a monoclonal and, therefore, neoplastic proliferation rather than a hyperplastic (polyclonal) proliferation as its name suggests.
Further evidence for the clonal nature of ADH is provided by a recent study in which it was found to be monoclonal with respect to X chromosome inactivation." A potential problem with this method is that the "patch" size with respect to X inactivation in the human breast has not, to the authors' knowledge, been determined. If it is large and includes whole lobules, then proliferations could arise from a large number of cells but still appear clonal. In addition, these authors did not clearly define their criteria for the diagnosis of ADH. Nevertheless, their study and the present one together provide strong evidence that ADH is a neoplastic process exhibiting at least some of the genetic changes which characterise established in situ and invasive breast carcinoma. There is thus a case for including ADH, as defined by Page and Rogers,6 within the spectrum ofductal carcinoma in situ, either using existing terminology or less specific nomenclature such as ductal in situ neoplasia.
It has become recognised in recent years that ductal carcinoma in situ is a heterogeneous group of proliferations in which the histological variants exhibit different clinical behaviour.'2 Subclassification of ductal carcinoma in situ has thus become a widely accepted necessity. To what extent ADH and low nuclear grade forms of ductal carcinoma in situ differ in their clinical behaviour requires further investigation. As the major problem of diagnosing ADH lies in distinguishing it from ductal carcinoma in situ of low nuclear grade,45 the inclusion ofADH within the spectrum of ductal carcinoma in situ might improve diagnostic consistency.
The finding of 16q and 17p deletions in ADH indicates that they are early events in the development of invasive cancer. We are undertaking further studies of a wide range of proliferative lesions to determine at which stage in the morphological evolution of breast cancer they are first detectable.
We have previously undertaken similar studies in lobular carcinoma in situ using the same technique. Allele loss on chromosome 1 6q was found with similar frequency to that seen in
